Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SEAL (Stopping Eczema and ALlergy) Study: Prevent the Allergic March by Enhancing the Skin Barrier

NCT03742414 is registered in ClinicalTrials.gov with Kari Nadeau, MD, PhD as lead sponsor.

NCT NCT03742414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03742414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SEAL (Stopping Eczema and ALlergy) Study: Prevent the Allergic March by Enhancing the Skin Barrier
Lead sponsor
Kari Nadeau, MD, PhD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2021
Completion date
June 30, 2028
Enrollment
398 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis eczema, eczema, eczema, infantile